Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rice

Showing results (411-420 of 435) with videos related to

Pageof 44
Sort By:
Science (New York, N.Y.)|November 17, 1995
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDSW G Rice, J G Supko, L Malspeis, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer TherapeuticsMustapha Haddach, Michael K Schwaebe, Jerome Michaux, et al.
Cancer Research|December 17, 2010
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growthDenis Drygin, Amy Lin, Josh Bliesath, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases InhibitorMustapha Haddach, Jerome Michaux, Michael K Schwaebe, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Placenta|December 10, 2013
IFPA Meeting 2013 Workshop Report II: use of 'omics' in understanding placental development, bioinformatics tools for gene expression analysis, planning and coordination of a placenta research network, placental imaging, evolutionary approaches to understanding pre-eclampsiaW E Ackerman, L Adamson, A M Carter, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Pageof 44

Showing results (411-420 of 435) with videos related to

Sort By:
Pageof 44
Science (New York, N.Y.)|November 17, 1995
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDSW G Rice, J G Supko, L Malspeis, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer TherapeuticsMustapha Haddach, Michael K Schwaebe, Jerome Michaux, et al.
Cancer Research|December 17, 2010
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growthDenis Drygin, Amy Lin, Josh Bliesath, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases InhibitorMustapha Haddach, Jerome Michaux, Michael K Schwaebe, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Placenta|December 10, 2013
IFPA Meeting 2013 Workshop Report II: use of 'omics' in understanding placental development, bioinformatics tools for gene expression analysis, planning and coordination of a placenta research network, placental imaging, evolutionary approaches to understanding pre-eclampsiaW E Ackerman, L Adamson, A M Carter, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Pageof 44